1.Vanguard Health Care Index Fund
VHT (NYSE Arca)
Vanguard Health Care Index Fund is a diversified U.S. healthcare ETF that provides broad sector exposure at a low cost, making it an attractive option for investors seeking to tap into the growing healthcare industry. With a strong 1-year return of 27.27% and a solid 5-year return of 24.08%, it also offers a dividend yield of 1.64%. This fund is well-positioned for those looking for reliable income streams combined with growth potential.
Pros:
- Diversified exposure to healthcare sector
- Low cost
Cons:
- Market fluctuations
- Sector-specific risks
2.SPDR S&P Biotech ETF
XBI (NYSE Arca)
The SPDR S&P Biotech ETF offers investors a robust avenue for gaining exposure to the dynamic sectors of drug development and innovation. With an impressive one-year return of 85.85% and a solid five-year return of 27.09%, this ETF stands out as a strong performer in the biotech space. Furthermore, it maintains a modest dividend yield of 0.39%, making it an appealing choice for those seeking growth alongside potential income.
Pros:
- Higher-growth exposure to drug development
- Strong recent performance
Cons:
- Higher volatility compared to broader market
- Sector-specific risks
3.Health Care Select Sector SPDR Fund
XLV (NYSE Arca)
The Health Care Select Sector SPDR Fund is a top-rated ETF that offers exposure to leading large-cap healthcare companies in the U.S. With a solid 1.69% dividend yield and impressive returns of 25.65% over the past year, it stands out as an attractive option for investors seeking reliable income from financially healthy firms. This fund is characterized by its high liquidity, making it a strategic choice for those looking to invest in the robust healthcare sector.
Pros:
- Broad exposure to large-cap healthcare leaders
- High liquidity
Cons:
- Sector-specific risks
- Market fluctuations
4.Veeva Systems Inc.
VEEV (NYSE)
Veeva Systems Inc. is a leading player in the U.S. healthcare software sector, catering specifically to life sciences and regulated healthcare workflows. Despite a challenging year with a return of -0.79% and a five-year decline of -11.85%, analysts remain optimistic, setting a median 12-month price target of $287.50 and maintaining a strong "A-" rating. Notably, firms like Needham and Guggenheim have reiterated their "Buy" recommendations, signaling confidence in the company's growth potential and market position.
Pros:
- Leader in healthcare software solutions
- Strong growth potential in life sciences
Cons:
- Recent underperformance
- Dependence on regulatory environments
5.Eli Lilly and Company
LLY (NYSE)
Eli Lilly and Company stands out as a top-rated large-cap healthcare stock, particularly noted for its robust growth in diabetes and obesity treatments. Delivering impressive returns of 60.80% over the past year and an extraordinary 354.49% over five years, it also offers a modest dividend yield of 0.57%. Analysts maintain a positive outlook, with a median 12-month price target of $1,360.00, reinforcing its attraction for investors seeking reliable growth in a financially strong sector.
Pros:
- Strong growth exposure in diabetes and obesity treatments
- High market cap of $1.11T
Cons:
- Market volatility risk
- Dependence on pharmaceutical approvals
6.Zoetis Inc.
ZTS (NYSE)
Zoetis Inc. stands out as a leading player in the U.S. animal health sector, characterized by its defensive healthcare exposure and consistent demand. Although the stock has seen a challenging 1-year return of -50.90% and a 5-year decline of -62.57%, it offers a dividend yield of 2.74%, making it an attractive option for income-focused investors. Analysts maintain a favorable view, with a median 12-month price target of $85.00 and ratings ranging from Buy to Outperform.
Pros:
- Leading position in animal health
- Recurring demand for veterinary products
Cons:
- Significant recent losses
- Market volatility risk
Final Words
As you consider investing in healthcare stocks this September, remember that options like Eli Lilly present strong growth potential in critical therapeutic areas. Take time to compare these opportunities and conduct your own research to make informed investment decisions that align with your financial goals.
Frequently Asked Questions
Eli Lilly and Company (LLY) has shown impressive performance in 2026, with a year-to-date return of 9.85% and a one-year return of 60.80%. Over the last three years, the stock has returned 113.13%.
Eli Lilly and Company has a dividend yield of approximately 0.57%. The next dividend payment is expected to be $1.7300, which is distributed quarterly.
Eli Lilly and Company has a market capitalization of $1.11 trillion, making it one of the largest healthcare stocks in the U.S. This positions it strongly for growth and stability compared to smaller competitors.
Investing in healthcare stocks like Eli Lilly comes with risks such as regulatory changes, competition, and market volatility. It's important for investors to assess these factors and consider their risk tolerance.
When comparing healthcare stocks, consider factors such as market cap, dividend yields, historical performance, and the company’s pipeline of products. Analyzing these aspects can help you make informed investment decisions.
Eli Lilly focuses on a range of treatments, primarily in diabetes and obesity, as well as oncology, autoimmune and inflammatory conditions, and neurological disorders. This diverse portfolio enhances its stability and growth potential.
